Patisiran maintained improvements in mNIS+7 and rapidly halted neurologic disease progression in hATTR amyloidosis.
American Association of Neuromuscular & Electrodiagnostic Medicine Annual Meeting (AANEM)
Subcutaneous immunoglobulin is an effective and well-tolerated alternative to intravenous immunoglobulin for myasthenia gravis.
Advertisement
Eculizumab showed sustained activity and tolerability through 3 years for generalized myasthenia gravis.
Advertisement
Advertisement
Trending on NeurologyLive - Clinical Neurology News and Neurology Expert Insights
1
Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook
2
CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS
3
FDA Approves Inebilizumab for Myasthenia Gravis, Phase 3 PREVAiLS Study Launched, Tolebrutinib Fails Phase 3 PERSEUS Study
4
Challenges with Commonly Available Dopamine Agonists in Parkinson’s Disease
5